MedTrace Logo

Anti-thymocyte Globulin-induced Immune Senescence

NCT02857907 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2016-08-05

No results posted yet for this study

Summary

The aim of the study is to investigate the impact of Anti-Thymocyte Globulin (ATG) on immune senescence. Markers of immune senescence expression is assessed in a prospective cohort of renal transplant recipients the day of transplantation and one year after renal transplantation.

Conditions

  • Disorder Related to Renal Transplantation

Interventions

OTHER

Blood sample

A blood sample is performed one year after kidney transplantation.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Principal Investigators

  • Jamal Bamoulid, Doctor · CHU Besançon

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02857907 on ClinicalTrials.gov